
HLUBF
Healthcare · Drug Manufacturers - Specialty & Generic · $8.86B market cap
$8.350.00 (0.0%)Nov 13, 9:30 AM EST
Latest report
After the close
The next earnings date isn’t on the calendar yet.
Analyst consensus
Fiscal period ending Dec 31, 2026
EPS trend, 90 days to now
Beat estimates in 0 of the last 4 reported quarters.
EPS surprise versus the estimate at the time of the report.
| Date | Session | Estimate | Actual | Surprise |
|---|---|---|---|---|
| Aug 19, 2026 | After the close | — | 0.18 | — |
| May 13, 2026 | After the close | — | 0.26 | — |
| Feb 3, 2026 | After the close | — | -0.00 | — |
| Nov 12, 2025 | After the close | — | 0.17 | — |
| Aug 20, 2025 | After the close | — | 0.15 | — |
| May 14, 2025 | Before the open | — | 0.16 | — |
| Feb 5, 2025 | Before the open | — | 0.09 | — |
| Nov 13, 2024 | Before the open | — | 0.12 | — |
| Aug 6, 2024 | Before the open | — | 0.11 | — |
| May 15, 2024 | Before the open | — | 0.15 | — |
| Mar 20, 2024 | Before the open | — | 0.02 | — |
H. Lundbeck A/S engages in the research, development, manufacturing, and commercializing pharmaceuticals for the treatment of psychiatric and neurological disorders in Europe, United States, and internationally. The company offers Abilify Maintena/ Abilify Asimtufii for schizophrenia and bipolar I disorder in adults; Brintellix/Trintellix to treat depressive disorders; Rexulti/Rxulti to treat major depressive…